AstraZeneca touts extended safety and efficacy data on Fasenra; Vanessa King takes the helm at Virion

→ AstraZeneca $AZN has rolled out a new round of safety and efficacy data they’ve been gathering from an extension study of Fasenra (benralizumab), their new drug for severe eosinophilic asthma. Researchers say they tracked an excellent safety profile at 56 weeks, adding: “74% of patients with a baseline blood eosinophil count of 300 cells per μL or greater (the primary efficacy population in the Phase III trials) who received FASENRA every eight weeks continuously from SIROCCO or CALIMA and into BORA, were exacerbation-free in BORA in their second year of treatment and maintained improvements in lung function and asthma control.”

→ Waltham, MA-based Entasis is the latest biotech to set terms for an IPO. The company plans to sell 4.4 million shares at $16 to $18 each, looking to raise about $75 million.

→ Experienced biotech vet Vanessa King has taken the CEO job at London-based Virion Biotherapeutics, building on a particle tech platform to focus on respiratory disease. King had been CEO at Luc Therapeutics and earlier worked the business development side of the table for deCODE, before Amgen bought out the company. Isabel Najera was also named as the company’s chief scientific officer.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->